naftopidil has been researched along with Urinary Tract Diseases in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy and safety of propiverine hydrochloride (antimuscarinic), naftopidil (alpha(1)-adrenoceptor antagonist) or both in patients with male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia and concomitant overactive bladder (OAB)." | 9.14 | Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. ( Kumon, H; Nagai, A; Sasaki, K; Uematsu, K; Watanabe, T; Yokoyama, T, 2009) |
| "To evaluate treatment failure during a 4-year follow-up period after administration of naftopidil for patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in real-life clinical practice." | 7.74 | Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. ( Hashimoto, J; Itoh, N; Masumori, N; Tsukamoto, T, 2007) |
| "To assess the efficacy and safety of propiverine hydrochloride (antimuscarinic), naftopidil (alpha(1)-adrenoceptor antagonist) or both in patients with male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia and concomitant overactive bladder (OAB)." | 5.14 | Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. ( Kumon, H; Nagai, A; Sasaki, K; Uematsu, K; Watanabe, T; Yokoyama, T, 2009) |
| "To evaluate treatment failure during a 4-year follow-up period after administration of naftopidil for patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in real-life clinical practice." | 3.74 | Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. ( Hashimoto, J; Itoh, N; Masumori, N; Tsukamoto, T, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yokoyama, T | 1 |
| Uematsu, K | 1 |
| Watanabe, T | 1 |
| Sasaki, K | 1 |
| Kumon, H | 1 |
| Nagai, A | 1 |
| Takeda, M | 1 |
| Homma, Y | 1 |
| Araki, I | 1 |
| Kakizaki, H | 1 |
| Yamanishi, T | 1 |
| Yokota, T | 1 |
| Gotoh, M | 1 |
| Igawa, Y | 1 |
| Seki, N | 1 |
| Takei, M | 1 |
| Yoshida, M | 1 |
| Sugaya, K | 1 |
| Nishizawa, O | 1 |
| Masumori, N | 1 |
| Hashimoto, J | 1 |
| Itoh, N | 1 |
| Tsukamoto, T | 1 |
2 trials available for naftopidil and Urinary Tract Diseases
| Article | Year |
|---|---|
Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Benzilates; Dose-Response Relationship, Drug; Drug Therapy, Comb | 2009 |
Predictive factors for the effect of the α1-D/A adrenoceptor antagonist naftopidil on subjective and objective criteria in patients with neurogenic lower urinary tract dysfunction.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Epidemiologic Methods; Fema | 2011 |
1 other study available for naftopidil and Urinary Tract Diseases
| Article | Year |
|---|---|
Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Kaplan-Meier Estimate; Male; Naphthalenes; Organ Size; P | 2007 |